Search

Your search keyword '"Baroni, Gianluca Svegliati"' showing total 150 results
Start Over Author "Baroni, Gianluca Svegliati"
150 results on '"Baroni, Gianluca Svegliati"'

1. Trends in liver transplantation for primary sclerosing cholangitis

Author

Viganò, Raffaella, Fornasiere, Ezio, Catanzaro, Elisa, Marrone, Giuseppe, Milana, Martina, Calleri, Alberto, Scorzoni, Chiara, Frassanito, Gabriella, Lionetti, Raffaella, Dibenedetto, Clara, Morelli, Maria Cristina, Gambato, Martina, Martini, Silvia, Carrai, Paola, Toniutto, Pierluigi, Giannelli, Valerio, Donato, Francesca, Lenci, Ilaria, Pasulo, Luisa, Mazzarelli, Chiara, Ferrarese, Alberto, Rendina, Maria, Grieco, Antonio, Lanza, Alfonso Galeota, Baroni, Gianluca Svegliati, De Maria, Nicola, Marenco, Simona, Mameli, Laura, Ponziani, Francesca Romana, Vitale, Giovanni, and Burra, Patrizia

Published
2024
Full Text
View/download PDF

2. Rare ATG7 genetic variants predispose patients to severe fatty liver disease

Author

Borroni, Vittorio, Liguori, Antonio, Ronzoni, Luisa, Cherubini, Alessandro, Santoro, Luigi, Tomasi, Melissa, Lombardi, Angela, Ostadreza, Mahnoosh, Casirati, Elia, Marini, Ilaria, Maier, Silvia, Rosso, Chiara, Baroni, Gianluca Svegliati, Santaniello, Carlo, Dallio, Marcello, Baselli, Guido A., Jamialahmadi, Oveis, Pelusi, Serena, Ciociola, Ester, Malvestiti, Francesco, Saracino, Marco, Dongiovanni, Paola, Maggioni, Marco, Bianco, Cristiana, Tavaglione, Federica, Cespiati, Annalisa, Mancina, Rosellina M., D’Ambrosio, Roberta, Vaira, Valentina, Petta, Salvatore, Miele, Luca, Vespasiani-Gentilucci, Umberto, Federico, Alessandro, Pihlajamaki, Jussi, Bugianesi, Elisabetta, Fracanzani, Anna L., Reeves, Helen L., Soardo, Giorgio, Prati, Daniele, Romeo, Stefano, and Valenti, Luca VC.

Published
2022
Full Text
View/download PDF

3. Comparison of prognostic models in advanced hepatocellular carcinoma patients undergoing Sorafenib: A multicenter study.

Author

Marasco, Giovanni, Colecchia, Antonio, Bacchi Reggiani, Maria Letizia, Celsa, Ciro, Farinati, Fabio, Giannini, Edoardo Giovanni, Benevento, Francesca, Rapaccini, Gian Ludovico, Caturelli, Eugenio, Di Marco, Mariella, Biasini, Elisabetta, Marra, Fabio, Morisco, Filomena, Foschi, Francesco Giuseppe, Zoli, Marco, Gasbarrini, Antonio, Baroni, Gianluca Svegliati, Masotto, Alberto, Sacco, Rodolfo, Raimondo, Giovanni, Azzaroli, Francesco, Mega, Andrea, Vidili, Gianpaolo, Brunetto, Maurizia Rossana, Nardone, Gerardo, Dajti, Elton, Ravaioli, Federico, Avanzato, Francesca, Festi, Davide, and Trevisani, Franco

Published
2021
Full Text
View/download PDF

4. Trends in liver transplantation for primary sclerosing cholangitis.

Author

Morelli, Maria Cristina, Gambato, Martina, Martini, Silvia, Carrai, Paola, Toniutto, Pierluigi, Giannelli, Valerio, Donato, Francesca, Lenci, Ilaria, Pasulo, Luisa, Mazzarelli, Chiara, Ferrarese, Alberto, Rendina, Maria, Grieco, Antonio, Lanza, Alfonso Galeota, Baroni, Gianluca Svegliati, De Maria, Nicola, Marenco, Simona, Mameli, Laura, Ponziani, Francesca Romana, and Vitale, Giovanni

Abstract

Primary sclerosing cholangitis is a cholestatic disease with a low prevalence in Italy. Indications for liver transplantation and the time of listing are not stated. We performed a national survey to investigate the listing criteria, comorbidities, and outcomes. In April 2022, we surveyed liver transplantation in primary sclerosing cholangitis nationwide for the last 15 years. From 2007 to 2021, 445 patients were included on waiting lists, and 411 had undergone liver transplants. The median age at transplantation was 46 years (males 63.9%); 262 patients (59%) presented an inflammatory bowel disease. Transplants increased over the years, from 1.8 % in 2007 to 3.0 % in 2021. Cholangitis (51%) and hepatic decompensation (45%) were the main indications for listing. The disease recurred in 81 patients (20%). Patient survival after the first transplant was 94 %, 86% and 84% at one, five, and ten years. Twenty-four died in the first year (50% surgical complications, 25% infections); 33 between one to five years (36% recurrence, 21% cholangiocarcinoma recurrence) and nine after five years (56% de novo cancer, 44% recurrence). Primary sclerosing cholangitis has been an increasing indication for transplantation in Italy. Cholangitis and decompensation were the main indications for listing. Recurrence and cancer were the leading causes of death. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

5. Liver Resection vs Nonsurgical Treatments for Patients With Early Multinodular Hepatocellular Carcinoma

Author

Vitale, Alessandro, Romano, Pierluigi, Cillo, Umberto, Lauterio, Andrea, Sangiovanni, Angelo, Cabibbo, Giuseppe, Missale, Gabriele, Marseglia, Mariarosaria, Trevisani, Franco, Foschi, Francesco Giuseppe, Cipriani, Federica, Famularo, Simone, Marra, Fabio, Saitta, Carlo, Serenari, Matteo, Vidili, Gianpaolo, Morisco, Filomena, Caturelli, Eugenio, Mega, Andrea, Pelizzaro, Filippo, Nicolini, Daniele, Ardito, Francesco, Garancini, Mattia, Masotto, Alberto, Baroni, Gianluca Svegliati, Azzaroli, Francesco, Giannini, Edoardo, Perri, Pasquale, Scarinci, Andrea, Fontana, Andrea Pierluigi, Brunetto, Maurizia Rossana, Iaria, Maurizio, Di Marco, Maria, Nardone, Gerardo, Dominioni, Tommaso, Lai, Quirino, Ferrari, Cecilia, Rapaccini, Gian Ludovico, Rodolfo, Sacco, Romano, Maurizio, Conci, Simone, Zoli, Marco, Conticchio, Maria, Zanello, Matteo, Zimmitti, Giuseppe, Fumagalli, Luca, Troci, Albert, Germani, Paola, Gasbarrini, Antonio, La Barba, Giuliano, De Angelis, Michela, Patauner, Stefan, Molfino, Sarah, Zago, Mauro, Pinotti, Enrico, Frigo, Anna Chiara, Baiocchi, Gian Luca, Frena, Antonio, Boccia, Luigi, Ercolani, Giorgio, Tarchi, Paola, Crespi, Michele, Chiarelli, Marco, Abu Hilal, Moh’d, Cescon, Matteo, Memeo, Riccardo, Ruzzenente, Andrea, Zanus, Giacomo, Griseri, Guido, Rossi, Massimo, Maestri, Marcello, Della Valle, Raffaele, Ferrero, Alessandro, Grazi, Gian Luca, Romano, Fabrizio, Giuliante, Felice, Vivarelli, Marco, Jovine, Elio, Torzilli, Guido, Aldrighetti, Luca, and De Carlis, Luciano

Abstract

IMPORTANCE: The 2022 Barcelona Clinic Liver Cancer algorithm currently discourages liver resection (LR) for patients with multinodular hepatocellular carcinoma (HCC) presenting with 2 or 3 nodules that are each 3 cm or smaller. OBJECTIVE: To compare the efficacy of liver resection (LR), percutaneous radiofrequency ablation (PRFA), and transarterial chemoembolization (TACE) in patients with multinodular HCC. DESIGN, SETTING, AND PARTICIPANTS: This cohort study is a retrospective analysis conducted using data from the HE.RC.O.LE.S register (n = 5331) for LR patients and the ITA.LI.CA database (n = 7056) for PRFA and TACE patients. A matching-adjusted indirect comparison (MAIC) method was applied to balance data and potential confounding factors between the 3 groups. Included were patients from multiple centers from 2008 to 2020; data were analyzed from January to December 2023. INTERVENTIONS: LR, PRFA, or TACE. MAIN OUTCOMES AND MEASURES: Survival rates at 1, 3, and 5 years were calculated. Cox MAIC-weighted multivariable analysis and competing risk analysis were used to assess outcomes. RESULTS: A total of 720 patients with early multinodular HCC were included, 543 males (75.4%), 177 females (24.6%), and 350 individuals older than 70 years (48.6%). There were 296 patients in the LR group, 240 who underwent PRFA, and 184 who underwent TACE. After MAIC, LR exhibited 1-, 3-, and 5-year survival rates of 89.11%, 70.98%, and 56.44%, respectively. PRFA showed rates of 94.01%, 65.20%, and 39.93%, while TACE displayed rates of 90.88%, 48.95%, and 29.24%. Multivariable Cox survival analysis in the weighted population showed a survival benefit over alternative treatments (PRFA vs LR: hazard ratio [HR], 1.41; 95% CI, 1.07-1.86; P = .01; TACE vs LR: HR, 1.86; 95% CI, 1.29-2.68; P = .001). Competing risk analysis confirmed a lower risk of cancer-related death in LR compared with PRFA and TACE. CONCLUSIONS AND RELEVANCE: For patients with early multinodular HCC who are ineligible for transplant, LR should be prioritized as the primary therapeutic option, followed by PRFA and TACE when LR is not feasible. These findings provide valuable insights for clinical decision-making in this patient population.

Published
2024
Full Text
View/download PDF

7. PB2189: UNUSUAL SITE THROMBOSIS IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS: THE EXPERIENCE WITH 66 CONSECUTIVE CASES.

Author

Morsia, Erika, primary, Ranalli, Paola, additional, Torre, Elena, additional, More’, Sonia, additional, Stefano, Baldoni, additional, Mancini, Stefania, additional, Battilà, Ilaria, additional, Martini, Francesco, additional, Tarantino, Giuseppe, additional, Baroni, Gianluca Svegliati, additional, Olivieri, Attilio, additional, Rupoli, Serena, additional, and Ianni, Mauro DI, additional

Published
2023
Full Text
View/download PDF

9. Hemostatic balance in patients with liver cirrhosis: Report of a consensus conference

Author

Andriulli, Angelo, Tripodi, Armando, Angeli, Paolo, Senzolo, Marco, Primignani, Massimo, Giannini, Edoardo G., Riggio, Oliviero, Colli, Agostino, Prati, Daniele, Sacerdoti, David, Merkel, Carlo, Basili, Stefania, Ferro, Domenico, Villa, Erica, Di Minno, Giovanni, Caraceni, Paolo, Marzioni, Marco, Mannucci, Pier Mannuccio, Violi, Francesco, Piscaglia, Fabio, Calvaruso, Vincenza, De Pietri, Lesley, Falcone, Marco, Feltracco, Paolo, Grandone, Elvira, La Mura, Vincenzo, Licata, Anna, Lucidi, Cristina, Maimone, Sergio, Marietta, Marco, Morisco, Filomena, Napoleone, Laura, Piano, Salvatore, Raparelli, Valeria, Rebulla, Paolo, Ribero, Dario, Sartori, Maria Teresa, Scalera, Antonella, Schepis, Filippo, Siciliano, Massimo, Baroni, Gianluca Svegliati, Tufano, Antonella, Vitale, Alessandro, and Zuin, Massimo

Published
2016
Full Text
View/download PDF

10. A “systems medicine” approach to the study of non-alcoholic fatty liver disease

Author

Ferrannini, Ele, Loguercio, Carmela, Lonardo, Amedeo, Marra, Fabio, Mancini, Marcello, Miele, Luca, Nobili, Valerio, Baroni, Gianluca Svegliati, Alessandro, Federico, Ballestri, Stefano, Rossana Brunetto, Maurizia, Coco, Barbara, Grieco, Antonio, Fargion, Silvia, Kondili, Loreta, Nascimbeni, Fabio, Prinster, Anna, Romagnoli, Dante, Taddei, Stefano, Vanni, Ester, Vella, Stefano, Petta, Salvatore, Valenti, Luca, Bugianesi, Elisabetta, Targher, Giovanni, Bellentani, Stefano, and Bonino, Ferruccio

Published
2016
Full Text
View/download PDF

12. PDX-1 mRNA expression in endoscopic ultrasound-guided fine needle cytoaspirate: Perspectives in the diagnosis of pancreatic cancer

Author

Marzioni, Marco, Germani, Ugo, Agostinelli, Laura, Bedogni, Giorgio, Saccomanno, Stefania, Marini, Francesco, Bellentani, Stefano, Barbera, Carmelo, De Minicis, Samuele, Rychlicki, Chiara, Santinelli, Alfredo, Ferretti, Maurizio, Di Maira, Pier Vittorio, Baroni, Gianluca Svegliati, Benedetti, Antonio, Caletti, Giancarlo, Lorenzini, Ivano, and Fusaroli, Pietro

Published
2015
Full Text
View/download PDF

13. Rare ATG7 genetic variants predispose patients to severe fatty liver disease

Author

Baselli, Guido A., primary, Jamialahmadi, Oveis, additional, Pelusi, Serena, additional, Ciociola, Ester, additional, Malvestiti, Francesco, additional, Saracino, Marco, additional, Santoro, Luigi, additional, Cherubini, Alessandro, additional, Dongiovanni, Paola, additional, Maggioni, Marco, additional, Bianco, Cristiana, additional, Tavaglione, Federica, additional, Cespiati, Annalisa, additional, Mancina, Rosellina M., additional, D’Ambrosio, Roberta, additional, Vaira, Valentina, additional, Petta, Salvatore, additional, Miele, Luca, additional, Vespasiani-Gentilucci, Umberto, additional, Federico, Alessandro, additional, Pihlajamaki, Jussi, additional, Bugianesi, Elisabetta, additional, Fracanzani, Anna L., additional, Reeves, Helen L., additional, Soardo, Giorgio, additional, Prati, Daniele, additional, Romeo, Stefano, additional, Valenti, Luca VC., additional, Borroni, Vittorio, additional, Liguori, Antonio, additional, Ronzoni, Luisa, additional, Tomasi, Melissa, additional, Lombardi, Angela, additional, Ostadreza, Mahnoosh, additional, Casirati, Elia, additional, Marini, Ilaria, additional, Maier, Silvia, additional, Rosso, Chiara, additional, Baroni, Gianluca Svegliati, additional, Santaniello, Carlo, additional, and Dallio, Marcello, additional

Published
2022
Full Text
View/download PDF

14. Hepatectomy Versus Sorafenib in Advanced Non-Metastatic Hepatocellular Carcinoma: A Real-Life Multicentric Weighted Comparison

Author

Famularo, Simone, Donadon, Matteo, Cipriani, Federica, Giuliante, Felice, Ferri, Silvia, Celsa, Ciro, Ferrero, Alessandro, Foschi, Francesco Giuseppe, Baiocchi, Gian Luca, Biasini, Elisabetta, Campani, Claudia, Valle, Raffaele Dalla, Pellizzaro, Filippo, Baroni, Gianluca Svegliati, Raimondo, Giovanni, Mega, Andrea, Chiarelli, Marco, Maestri, Marcello, Gasbarrini, Antonio, Jovine, Elio, Grazi, Gian Luca, Rapaccini, Gian Ludovico, Ruzzenente, Andrea, Morisco, Filomena, Sacco, Rodolfo, Memeo, Riccardo, Crespi, Michele, Antonucci, Adelmo, Bernasconi, Davide P, Romano, Fabrizio, Griseri, Guido, Aldrighetti, Luca, Torzilli, Guido, Trevisani, Franco, Famularo, S, Donadon, M, Cipriani, F, Giuliante, F, Ferri, S, Celsa, C, Ferrero, A, Foschi, F, Baiocchi, G, Biasini, E, Campani, C, Valle, R, Pellizzaro, F, Baroni, G, Raimondo, G, Mega, A, Chiarelli, M, Maestri, M, Gasbarrini, A, Jovine, E, Grazi, G, Rapaccini, G, Ruzzenente, A, Morisco, F, Sacco, R, Memeo, R, Crespi, M, Antonucci, A, Bernasconi, D, Romano, F, Griseri, G, Aldrighetti, L, Torzilli, G, Trevisani, F, Famularo, Simone, Donadon, Matteo, Cipriani, Federica, Giuliante, Felice, Ferri, Silvia, Celsa, Ciro, Ferrero, Alessandro, Foschi, Francesco Giuseppe, Baiocchi, Gian Luca, Biasini, Elisabetta, Campani, Claudia, Valle, Raffaele Dalla, Pelizzaro, Filippo, Baroni, Gianluca Svegliati, Raimondo, Giovanni, Mega, Andrea, Chiarelli, Marco, Maestri, Marcello, Gasbarrini, Antonio, Jovine, Elio, Grazi, Gian Luca, Rapaccini, Gian Ludovico, Ruzzenente, Andrea, Morisco, Filomena, Sacco, Rodolfo, Memeo, Riccardo, Crespi, Michele, Antonucci, Adelmo, Bernasconi, Davide P, Romano, Fabrizio, Griseri, Guido, Aldrighetti, Luca, Torzilli, Guido, Trevisani, Franco, and Pellizzaro, Filippo

Subjects
Niacinamide, Carcinoma, Hepatocellular, Hepatocellular carcinoma, hepatocellular carcinoma, surgery, sorafenib, bclc, Phenylurea Compounds, Carcinoma, Settore MED/09 - MEDICINA INTERNA, Liver Neoplasms, advanced HCC, Hepatocellular, Antineoplastic Agents, systemic therapies, Sorafenib, BCLC C, NO, Treatment Outcome, macrovascular invasion, Humans, Hepatectomy, Surgery, Neoplasm Staging, Retrospective Studies, Liver surgery
Abstract

Objective: The aim of the study was to compare SURG vs SOR regarding the OS and progression-free survival (PFS) in a real-world clinical scenario. Background data: The treatment for advanced nonmetastatic HCC belonging to the Barcelona Clinic Liver Cancer stage C (BCLC C) is still controversial. Methods: BCLC C patients without extrahepatic spread and tumoral invasion of the main portal trunk were considered. Surgical patients were obtained from the HE.RC.O.LE.S. Register, whereas sorafenib patients were obtained from the ITA.LI.CA register The inverse probability weighting (IPW) method was adopted to balance the confounders between the 2 groups. Results: Between 2008 and 2019, 478 patients were enrolled: 303 in SURG and 175 in SOR group. Eastern Cooperative Oncological Group Performance Status (ECOG-PS), presence of cirrhosis, steatosis, Child-Pugh grade, hepatitis B virus and hepatitis C virus, alcohol intake, collateral veins, bilobar disease, localization of the tumor thrombus, number of nodules, alpha-fetoprotein, age, and Charlson Comorbidity index were weighted by IPW to create two balanced pseudo-populations: SURG = 374 and SOR = 263. After IPW, 1-3-5 years OS was 83.6%, 68.1%, 55.9% for SURG, and 42.3%, 17.8%, 12.8% for SOR (P < 0.001). Similar trends were observed after subgrouping patients by ECOG-PS = 0 and ECOG-PS >0, and by the intrahepatic location of portal vein invasion. At Cox regression, sorafenib treatment (hazard ratio 4.436; 95% confidence interval 3.19-6.15; P < 0.001) and Charlson Index (hazard ratio 1.162; 95% confidence interval 1.06-1.27; P = 0.010) were the only independent predictors of mortality. PFS at 1-3-5 years were 65.9%, 40.3%, 24.3% for SURG and 21.6%, 3.5%, 2.9% for SOR (P = 0.007). Conclusions: In BCLC C patients without extrahepatic spread but with intrahepatic portal invasion, liver resection, if feasible, was followed by better OS and PFS compared with sorafenib.

Published
2022

15. The Role of Transjugular Intrahepatic Portosystemic Shunt (TIPS) in Treating Portal Hypertension in Patients with Hepatocellular Carcinoma.

Author

Balducci, Daniele, Montori, Michele, De Blasio, Federico, Di Bucchianico, Alessandro, Argenziano, Maria Eva, Baroni, Gianluca Svegliati, and Scarpellini, Emidio

Subjects
PORTAL hypertension, PATIENT portals, HEPATOCELLULAR carcinoma, HYPERTENSION, PORTAL vein diseases, FATTY liver
Abstract

Liver cancer is very frequent, and hepatocellular carcinoma (HCC) accounts for the majority of liver cancer cases. Its growing incidence has been greatly affected by the increasing prevalence of metabolic-associated fatty liver disease (MAFLD). The latter is a new epidemic in our era. In fact, HCC is often generated from noncirrhotic liver and its treatment benefits from surgical and nonsurgical approaches, potentially bridged by transjugular intrahepatic portosystemic shunt (TIPS) use. TIPS use is an effective treatment for portal hypertension complications, but its application in patients with HCC and clinically significant portal hypertension (CSPH) remains controversial due to concerns about tumor rupture, dissemination, and increased toxicity. The technical feasibility and safety of TIPS use in HCC patients have been evaluated in several studies. Despite concerns about intraprocedural complications, retrospective studies have shown high success rates and low complication rates in TIPS placement for HCC patients. TIPS use in combination with locoregional treatments, such as transarterial chemoembolization (TACE) or transarterial radioembolization (TARE), has been explored as a treatment option for HCC patients with portal hypertension. These studies have shown improved survival rates in patients undergoing TIPS in combination with locoregional treatments. However, the efficacy and toxicity of TACE in combination with TIPS use require careful evaluation, as changes in venous and arterial flow can affect treatment outcomes and complications. The results from studies evaluating the impact of TIPS on systemic therapy and surgical options are also promising. In conclusion, the TIPS is a sufficiently safe, useful item available for physicians treating complications of portal hypertension. Moreover, a TIPS can be used in combination with locoregional therapy in HCC patients. Systemic chemotherapy can also benefit of the use of TIPS placement. A complex interplay affects TIPS use with surgery. The latter needs further data. The TIPS is a useful and safe add-on treatment, changing the natural course of HCC progression. Its use is regulated by a sophisticated physiologic and pathophysiologic flow of evidence. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

17. Hepatectomy Versus Sorafenib in Advanced Nonmetastatic Hepatocellular Carcinoma: A Real-life Multicentric Weighted Comparison

Author

Famularo, Simone, Donadon, Matteo, Cipriani, Federica, Giuliante, Felice, Ferri, Silvia, Celsa, Ciro, Ferrero, Alessandro, Foschi, Francesco Giuseppe, Baiocchi, Gian Luca, Biasini, Elisabetta, Campani, Claudia, Valle, Raffaele Dalla, Pelizzaro, Filippo, Baroni, Gianluca Svegliati, Raimondo, Giovanni, Mega, Andrea, Chiarelli, Marco, Maestri, Marcello, Gasbarrini, Antonio, Jovine, Elio, Grazi, Gian Luca, Rapaccini, Gian Ludovico, Ruzzenente, Andrea, Morisco, Filomena, Sacco, Rodolfo, Memeo, Riccardo, Crespi, Michele, Antonucci, Adelmo, Bernasconi, Davide P, Romano, Fabrizio, Griseri, Guido, Aldrighetti, Luca, Torzilli, Guido, Trevisani, Franco, Giuliante, Felice (ORCID:0000-0001-9517-8220), Gasbarrini, Antonio (ORCID:0000-0002-7278-4823), Rapaccini, Gian Ludovico (ORCID:0000-0002-6467-857X), Famularo, Simone, Donadon, Matteo, Cipriani, Federica, Giuliante, Felice, Ferri, Silvia, Celsa, Ciro, Ferrero, Alessandro, Foschi, Francesco Giuseppe, Baiocchi, Gian Luca, Biasini, Elisabetta, Campani, Claudia, Valle, Raffaele Dalla, Pelizzaro, Filippo, Baroni, Gianluca Svegliati, Raimondo, Giovanni, Mega, Andrea, Chiarelli, Marco, Maestri, Marcello, Gasbarrini, Antonio, Jovine, Elio, Grazi, Gian Luca, Rapaccini, Gian Ludovico, Ruzzenente, Andrea, Morisco, Filomena, Sacco, Rodolfo, Memeo, Riccardo, Crespi, Michele, Antonucci, Adelmo, Bernasconi, Davide P, Romano, Fabrizio, Griseri, Guido, Aldrighetti, Luca, Torzilli, Guido, Trevisani, Franco, Giuliante, Felice (ORCID:0000-0001-9517-8220), Gasbarrini, Antonio (ORCID:0000-0002-7278-4823), and Rapaccini, Gian Ludovico (ORCID:0000-0002-6467-857X)

Abstract

Objective: The aim of the study was to compare SURG vs SOR regarding the OS and progression-free survival (PFS) in a real-world clinical scenario. Background data: The treatment for advanced nonmetastatic HCC belonging to the Barcelona Clinic Liver Cancer stage C (BCLC C) is still controversial. Methods: BCLC C patients without extrahepatic spread and tumoral invasion of the main portal trunk were considered. Surgical patients were obtained from the HE.RC.O.LE.S. Register, whereas sorafenib patients were obtained from the ITA.LI.CA register The inverse probability weighting (IPW) method was adopted to balance the confounders between the 2 groups. Results: Between 2008 and 2019, 478 patients were enrolled: 303 in SURG and 175 in SOR group. Eastern Cooperative Oncological Group Performance Status (ECOG-PS), presence of cirrhosis, steatosis, Child-Pugh grade, hepatitis B virus and hepatitis C virus, alcohol intake, collateral veins, bilobar disease, localization of the tumor thrombus, number of nodules, alpha-fetoprotein, age, and Charlson Comorbidity index were weighted by IPW to create two balanced pseudo-populations: SURG = 374 and SOR = 263. After IPW, 1-3-5 years OS was 83.6%, 68.1%, 55.9% for SURG, and 42.3%, 17.8%, 12.8% for SOR (P < 0.001). Similar trends were observed after subgrouping patients by ECOG-PS = 0 and ECOG-PS >0, and by the intrahepatic location of portal vein invasion. At Cox regression, sorafenib treatment (hazard ratio 4.436; 95% confidence interval 3.19-6.15; P < 0.001) and Charlson Index (hazard ratio 1.162; 95% confidence interval 1.06-1.27; P = 0.010) were the only independent predictors of mortality. PFS at 1-3-5 years were 65.9%, 40.3%, 24.3% for SURG and 21.6%, 3.5%, 2.9% for SOR (P = 0.007). Conclusions: In BCLC C patients without extrahepatic spread but with intrahepatic portal invasion, liver resection, if feasible, was followed by better OS and PFS compared with sorafenib.

Published
2022

18. Hepatectomy Versus Sorafenib in Advanced Non-Metastatic Hepatocellular Carcinoma: A Real-Life Multicentric Weighted Comparison

Author

Famularo, S, Donadon, M, Cipriani, F, Giuliante, F, Ferri, S, Celsa, C, Ferrero, A, Foschi, F, Baiocchi, G, Biasini, E, Campani, C, Valle, R, Pellizzaro, F, Baroni, G, Raimondo, G, Mega, A, Chiarelli, M, Maestri, M, Gasbarrini, A, Jovine, E, Grazi, G, Rapaccini, G, Ruzzenente, A, Morisco, F, Sacco, R, Memeo, R, Crespi, M, Antonucci, A, Bernasconi, D, Romano, F, Griseri, G, Aldrighetti, L, Torzilli, G, Trevisani, F, Famularo, Simone, Donadon, Matteo, Cipriani, Federica, Giuliante, Felice, Ferri, Silvia, Celsa, Ciro, Ferrero, Alessandro, Foschi, Francesco Giuseppe, Baiocchi, Gian Luca, Biasini, Elisabetta, Campani, Claudia, Valle, Raffaele Dalla, Pellizzaro, Filippo, Baroni, Gianluca Svegliati, Raimondo, Giovanni, Mega, Andrea, Chiarelli, Marco, Maestri, Marcello, Gasbarrini, Antonio, Jovine, Elio, Grazi, Gian Luca, Rapaccini, Gian Ludovico, Ruzzenente, Andrea, Morisco, Filomena, Sacco, Rodolfo, Memeo, Riccardo, Crespi, Michele, Antonucci, Adelmo, Bernasconi, Davide P, Romano, Fabrizio, Griseri, Guido, Aldrighetti, Luca, Torzilli, Guido, Trevisani, Franco, Famularo, S, Donadon, M, Cipriani, F, Giuliante, F, Ferri, S, Celsa, C, Ferrero, A, Foschi, F, Baiocchi, G, Biasini, E, Campani, C, Valle, R, Pellizzaro, F, Baroni, G, Raimondo, G, Mega, A, Chiarelli, M, Maestri, M, Gasbarrini, A, Jovine, E, Grazi, G, Rapaccini, G, Ruzzenente, A, Morisco, F, Sacco, R, Memeo, R, Crespi, M, Antonucci, A, Bernasconi, D, Romano, F, Griseri, G, Aldrighetti, L, Torzilli, G, Trevisani, F, Famularo, Simone, Donadon, Matteo, Cipriani, Federica, Giuliante, Felice, Ferri, Silvia, Celsa, Ciro, Ferrero, Alessandro, Foschi, Francesco Giuseppe, Baiocchi, Gian Luca, Biasini, Elisabetta, Campani, Claudia, Valle, Raffaele Dalla, Pellizzaro, Filippo, Baroni, Gianluca Svegliati, Raimondo, Giovanni, Mega, Andrea, Chiarelli, Marco, Maestri, Marcello, Gasbarrini, Antonio, Jovine, Elio, Grazi, Gian Luca, Rapaccini, Gian Ludovico, Ruzzenente, Andrea, Morisco, Filomena, Sacco, Rodolfo, Memeo, Riccardo, Crespi, Michele, Antonucci, Adelmo, Bernasconi, Davide P, Romano, Fabrizio, Griseri, Guido, Aldrighetti, Luca, Torzilli, Guido, and Trevisani, Franco

Abstract

OBJECTIVE: The aim of the study was to compare SURG vs SOR regarding the OS and progression-free survival (PFS) in a real-world clinical scenario. BACKGROUND DATA: The treatment for advanced nonmetastatic HCC belonging to the Barcelona Clinic Liver Cancer stage C (BCLC C) is still controversial. METHODS: BCLC C patients without extrahepatic spread and tumoral invasion of the main portal trunk were considered. Surgical patients were obtained from the HE.RC.O.LE.S. Register, whereas sorafenib patients were obtained from the ITA.LI.CA register The inverse probability weighting (IPW) method was adopted to balance the confounders between the 2 groups. RESULTS: Between 2008 and 2019, 478 patients were enrolled: 303 in SURG and 175 in SOR group. Eastern Cooperative Oncological Group Performance Status (ECOG-PS), presence of cirrhosis, steatosis, Child-Pugh grade, hepatitis B virus and hepatitis C virus, alcohol intake, collateral veins, bilobar disease, localization of the tumor thrombus, number of nodules, alpha-fetoprotein, age, and Charlson Comorbidity index were weighted by IPW to create two balanced pseudo-populations: SURG = 374 and SOR = 263. After IPW, 1-3-5 years OS was 83.6%, 68.1%, 55.9% for SURG, and 42.3%, 17.8%, 12.8% for SOR (P [removed]0, and by the intrahepatic location of portal vein invasion. At Cox regression, sorafenib treatment (hazard ratio 4.436; 95% confidence interval 3.19-6.15; P < 0.001) and Charlson Index (hazard ratio 1.162; 95% confidence interval 1.06-1.27; P = 0.010) were the only independent predictors of mortality. PFS at 1-3-5 years were 65.9%, 40.3%, 24.3% for SURG and 21.6%, 3.5%, 2.9% for SOR (P = 0.007). CONCLUSIONS: In BCLC C patients without extrahepatic spread but with intrahepatic portal invasion, liver resection, if feasible, was followed by better OS and PFS compared with sorafenib.

Published
2022

19. Curative therapies are superior to standard of care (transarterial chemoembolization) for intermediate stage hepatocellular carcinoma

Author

Pecorelli, Anna, Lenzi, Barbara, Gramenzi, Annagiulia, Garuti, Francesca, Farinati, Fabio, Giannini, Edoardo G., Ciccarese, Francesca, Piscaglia, Fabio, Rapaccini, Gian Lodovico, Di Marco, Maria, Caturelli, Eugenio, Zoli, Marco, Borzio, Franco, Sacco, Rodolfo, Cabibbo, Giuseppe, Felder, Martina, Morisco, Filomena, Gasbarrini, Antonio, Baroni, Gianluca Svegliati, Foschi, Francesco G., Biasini, Elisabetta, Masotto, Alberto, Virdone, Roberto, Bernardi, Mauro, Trevisani, Franco, Bolondi, Luigi, Biselli, Maurizio, Bucci, Laura, Caraceni, Paolo, Cucchetti, Alessandro, Domenicali, Marco, Magalotti, Donatella, Serra, Carla, Venerandi, Laura, Giacomin, Anna, Maddalo, Gemma, Pozzan, Caterina, Vani, Veronica, Poggio, Paolo Del, Olmi, Stefano, Balsamo, Claudia, Vavassori, Elena, Benvegnù, Luisa, Cappelli, Alberta, Golfieri, Rita, Mosconi, Cristina, Renzulli, Matteo, Bosco, Giulia, Roselli, Paola, DellʼIsola, Serena, Ialungo, Anna Maria, Bruzzone, Linda, Picciotto, Antonino, Marenco, Simona, Risso, Domenico, Sammito, Giorgio, Savarino, Vincenzo, Cammà, Calogero, Maida, Marcello, Costantino, Andrea, Barcellona, Maria Rosa, Affronti, Andrea, Mega, Andrea, Rinninella, Emanuele, Mismas, Valeria, Cappa, Federica Mirici, DallʼAglio, Anna Chiara, Feletti, Valentina, Lanzi, Arianna, Neri, Elga, Stefanini, Giuseppe Francesco, Tamberi, Stefano, Missale, Gabriele, Porro, Emanuela, Guarino, Maria, Gemini, Stefano, and Schiadà, Laura

Published
2017
Full Text
View/download PDF

20. Performance of the model for end-stage liver disease score for mortality prediction and the potential role of etiology

Author

D’Amico, Gennaro, primary, Maruzzelli, Luigi, additional, Airoldi, Aldo, additional, Petridis, Ioannis, additional, Tosetti, Giulia, additional, Rampoldi, Antonio, additional, D’Amico, Mario, additional, Miraglia, Roberto, additional, De Nicola, Stella, additional, La Mura, Vincenzo, additional, Solcia, Marco, additional, Volpes, Riccardo, additional, Perricone, Giovanni, additional, Sgrazzutti, Cristiano, additional, Vanzulli, Angelo, additional, Primignani, Massimo, additional, Luca, Angelo, additional, Malizia, Giuseppe, additional, Federico, Alessandro, additional, Dallio, Marcello, additional, Andriulli, Angelo, additional, Iacobellis, Angelo, additional, Addario, Luigi, additional, Garcovich, Matteo, additional, Gasbarrini, Antonio, additional, Chessa, Luchino, additional, Salerno, Francesco, additional, Gobbo, Giulia, additional, Merli, Manuela, additional, Ridola, Lorenzo, additional, Baroni, Gianluca Svegliati, additional, Tarantino, Giuseppe, additional, Caporaso, Nicola, additional, Morisco, Filomena, additional, Pozzoni, Pietro, additional, Colli, Agostino, additional, and Belli, Luca Saverio, additional

Published
2021
Full Text
View/download PDF

21. Years of life that could be saved from prevention of hepatocellular carcinoma

Author

Cucchetti, A., Trevisani, F., Bucci, L., Ravaioli, M., Farinati, F., Giannini, E. G., Ciccarese, F., Piscaglia, F., Rapaccini, G. L., Di Marco, M., Caturelli, E., Zoli, M., Borzio, F., Sacco, R., Maida, M., Felder, M., Morisco, F., Gasbarrini, A., Gemini, S., Foschi, F. G., Missale, G., Masotto, A., Affronti, A., Bernardi, M., Pinna, A. D., Bolondi, Luigi, Biselli, Maurizio, Caraceni, Paolo, Domenicali, Marco, Gramenzi, Annagiulia, Magalotti, Donatella, Pecorelli, Anna, Serra, Carla, Venerandi, Laura, Gazzola, Alessia, Murer, Francesca, Pozzan, Caterina, Vanin, Veronica, Poggio, Paolo Del, Olmi, Stefano, Balsamo, Claudia, Vavassori, Elena, Benvegnù, Luisa, Cappelli, Alberta, Golfieri, Rita, Mosconi, Cristina, Renzulli, Matteo, Bosco, Giulia, Roselli, Paola, DellʼIsola, Serena, Lalungo, Anna Maria, Rastrelli, Elena, Moscatelli, Alessandro, Pellegatta, Gaia, Picciotto, Antonino, Savarino, Vincenzo, Barcellona, Maria Rosa, Virdone, Roberto, Mega, Andrea, Rinninella, Emanuele, Mismas, Valeria, DallʼAglio, Anna Chiara, Feletti, Valentina, Lanzi, Arianna, Cappa, Federica Mirici, Neri, Elga, Stefanini, Giuseppe Francesco, Tamberi, Stefano, Guarino, Maria, Baroni, Gianluca Svegliati, Schiadà, Laura, Chiaramonte, Maria, Marchetti, Fabiana, and Valerio, Matteo

Published
2016
Full Text
View/download PDF

22. Comparison between alcohol- and hepatitis C virus-related hepatocellular carcinoma: clinical presentation, treatment and outcome

Author

Bucci, L., Garuti, F., Camelli, V., Lenzi, B., Farinati, F., Giannini, E. G., Ciccarese, F., Piscaglia, F., Rapaccini, G. L., Di Marco, M., Caturelli, E., Zoli, M., Borzio, F., Sacco, R., Maida, M., Felder, M., Morisco, F., Gasbarrini, A., Gemini, S., Foschi, F. G., Missale, G., Masotto, A., Affronti, A., Bernardi, M., Trevisani, F., Bolondi, Luigi, Biselli, Maurizio, Caraceni, Paolo, Cucchetti, Alessandro, Domenicali, Marco, Gramenzi, Annagiulia, Magalotti, Donatella, Pecorelli, Anna, Serra, Carla, Venerandi, Laura, Gazzola, Alessia, Murer, Francesca, Pozzan, Caterina, Vanin, Veronica, Poggio, Paolo Del, Olmi, Stefano, Balsamo, Claudia, Vavassori, Elena, Benvegnù, Luisa, Capelli, Alberta, Golfieri, Rita, Mosconi, Cristina, Renzulli, Matteo, Roselli, Paola, Isola, Serena, Ialungo, Anna Maria, Rastrelli, Elena, Moscatelli, Alessandro, Pelagatta, Gaia, Picciotto, Antonino, Savarino, Vincenzo, Barcellona, Maria Rosa, Cammà, Calogero, Cabibbo, Giuseppe, Costantino, Andrea, Virdone, Roberto, Mega, Andrea, Rinninella, Emanuele, Mismas, Valeria, DallʼAglio, Anna Chiara, Feletti, Valentina, Lanzi, Arianna, Cappa, Federica Mirici, Neri, Elga, Stefanini, Giuseppe Francesco, Tamberi, Stefano, Biasini, Elisabetta, Porro, Emanuela, Guarino, Maria, Baroni, Gianluca Svegliati, Schiadà, Laura, Chiaramonte, Maria, Marchetti, Fabiana, and Valerio, Matteo

Published
2016
Full Text
View/download PDF

23. Correction: Application of the Intermediate-Stage Subclassification to Patients With Untreated Hepatocellular Carcinoma

Author

Giannini, Edoardo G., Moscatelli, Alessandro, Pellegatta, Gaia, Vitale, Alessandro, Farinati, Fabio, Ciccarese, Francesca, Piscaglia, Fabio, Rapaccini, Gian Lodovico, Di Marco, Maria, Caturelli, Eugenio, Zoli, Marco, Borzio, Franco, Cabibbo, Giuseppe, Felder, Martina, Sacco, Rodolfo, Morisco, Filomena, Missale, Gabriele, Foschi, Francesco Giuseppe, Gasbarrini, Antonio, Baroni, Gianluca Svegliati, Virdone, Roberto, Masotto, Alberto, Trevisani, Franco, and and the Italian Liver Cancer (ITA.LI.CA) Group

Published
2018
Full Text
View/download PDF

25. Performance of the model for end-stage liver disease score for mortality prediction and the potential role of etiology

Author

D'Amico, G, Maruzzelli, L, Airoldi, A, Petridis, I, Tosetti, G, Rampoldi, A, D'Amico, M, Miraglia, R, De Nicola, S, La Mura, V, Solcia, M, Volpes, R, Perricone, G, Sgrazzutti, C, Vanzulli, A, Primignani, M, Luca, A, Malizia, G, Federico, A, Dallio, M, Andriulli, A, Iacobellis, A, Addario, L, Garcovich, M, Gasbarrini, A, Chessa, L, Salerno, F, Gobbo, G, Merli, M, Ridola, L, Baroni, G, Tarantino, G, Caporaso, N, Morisco, F, Pozzoni, P, Colli, A, Belli, L, D'Amico, Gennaro, Maruzzelli, Luigi, Airoldi, Aldo, Petridis, Ioannis, Tosetti, Giulia, Rampoldi, Antonio, D'Amico, Mario, Miraglia, Roberto, De Nicola, Stella, La Mura, Vincenzo, Solcia, Marco, Volpes, Riccardo, Perricone, Giovanni, Sgrazzutti, Cristiano, Vanzulli, Angelo, Primignani, Massimo, Luca, Angelo, Malizia, Giuseppe, Federico, Alessandro, Dallio, Marcello, Andriulli, Angelo, Iacobellis, Angelo, Addario, Luigi, Garcovich, Matteo, Gasbarrini, Antonio, Chessa, Luchino, Salerno, Francesco, Gobbo, Giulia, Merli, Manuela, Ridola, Lorenzo, Baroni, Gianluca Svegliati, Tarantino, Giuseppe, Caporaso, Nicola, Morisco, Filomena, Pozzoni, Pietro, Colli, Agostino, Belli, Luca Saverio, D'Amico, G, Maruzzelli, L, Airoldi, A, Petridis, I, Tosetti, G, Rampoldi, A, D'Amico, M, Miraglia, R, De Nicola, S, La Mura, V, Solcia, M, Volpes, R, Perricone, G, Sgrazzutti, C, Vanzulli, A, Primignani, M, Luca, A, Malizia, G, Federico, A, Dallio, M, Andriulli, A, Iacobellis, A, Addario, L, Garcovich, M, Gasbarrini, A, Chessa, L, Salerno, F, Gobbo, G, Merli, M, Ridola, L, Baroni, G, Tarantino, G, Caporaso, N, Morisco, F, Pozzoni, P, Colli, A, Belli, L, D'Amico, Gennaro, Maruzzelli, Luigi, Airoldi, Aldo, Petridis, Ioannis, Tosetti, Giulia, Rampoldi, Antonio, D'Amico, Mario, Miraglia, Roberto, De Nicola, Stella, La Mura, Vincenzo, Solcia, Marco, Volpes, Riccardo, Perricone, Giovanni, Sgrazzutti, Cristiano, Vanzulli, Angelo, Primignani, Massimo, Luca, Angelo, Malizia, Giuseppe, Federico, Alessandro, Dallio, Marcello, Andriulli, Angelo, Iacobellis, Angelo, Addario, Luigi, Garcovich, Matteo, Gasbarrini, Antonio, Chessa, Luchino, Salerno, Francesco, Gobbo, Giulia, Merli, Manuela, Ridola, Lorenzo, Baroni, Gianluca Svegliati, Tarantino, Giuseppe, Caporaso, Nicola, Morisco, Filomena, Pozzoni, Pietro, Colli, Agostino, and Belli, Luca Saverio

Abstract

Although discrimination of the model for end stage liver disease (MELD) is generally considered acceptable, its calibration is still unclear. In a validation study, we assessed the discrimination and calibration performance of 3 versions of the model: original MELD-TIPS, used to predict survival after transjugular intra-hepatic portosystemic shunt (TIPS); classic MELD-Mayo; MELD-UNOS, used by United Network for Organ Sharing (UNOS). Recalibration and model updating were also explored.

Published
2021

27. VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: The ALICE-1 study

Author

Scartozzi, Mario, Faloppi, Luca, Baroni, Gianluca Svegliati, Loretelli, Cristian, Piscaglia, Fabio, Iavarone, Massimo, Toniutto, Pierluigi, Fava, Giammarco, De Minicis, Samuele, Mandolesi, Alessandra, Bianconi, Maristella, Giampieri, Riccardo, Granito, Alessandro, Facchetti, Floriana, Bitetto, Davide, Marinelli, Sara, Venerandi, Laura, Vavassori, Sara, Gemini, Stefano, DʼErrico, Antonietta, Colombo, Massimo, Bolondi, Luigi, Bearzi, Italo, Benedetti, Antonio, and Cascinu, Stefano

Published
2014
Full Text
View/download PDF

28. Determinants of alpha-fetoprotein levels in patients with hepatocellular carcinoma: Implications for its clinical use

Author

Giannini, Edoardo G., Sammito, Giorgio, Farinati, Fabio, Ciccarese, Francesca, Pecorelli, Anna, Rapaccini, Gian Lodovico, Di Marco, Mariella, Caturelli, Eugenio, Zoli, Marco, Borzio, Franco, Cabibbo, Giuseppe, Felder, Martina, Gasbarrini, Antonio, Sacco, Rodolfo, Foschi, Francesco Giuseppe, Missale, Gabriele, Morisco, Filomena, Baroni, Gianluca Svegliati, Virdone, Roberto, and Trevisani, Franco

Published
2014
Full Text
View/download PDF

29. Cell proliferation and drug resistance in hepatocellular carcinoma are modulated by Rho GTPase signals

Author

Sterpetti, Paola, Marucci, Luca, Candelaresi, Cinzia, Toksoz, Deniz, Alpini, Gianfranco, Ugili, Laura, Baroni, Gianluca Svegliati, Macarri, Giampiero, and Benedetti, Antonio

Subjects
Cell cycle -- Research, Oncogenes -- Research, Oncogenes -- Analysis, Hepatoma -- Research, Hepatoma -- Analysis, Biological sciences
Abstract

Hepatocellular carcinoma is highly resistant to chemotherapeutic agents, thus the need to discover effective therapeutic molecules to suppress cancer cell growth and to overcome drug resistance is urgent. The Rho GTPase is implicated in cancer and metastasis and is directly activated by the Lymphoid blast crisis (Lbc) protooncogene, a Rho guanine-nucleotide exchange factor. The aim of the study was to analyze the expression of Lbc in hepatocarcinoma and to determine the effect of Lbc-induced Rho signaling on expression, growth rate and resistance to genotoxic stress. We found, by immunohistochemical analysis of biopsy samples and Northern and Western blot analyses of cell lines, that Lbc is absent in normal adult liver but is abundantly expressed in hepatocarcinoma, implying an increased Rho pathway signaling. Lbc stably transfected hepatocarcinoma cells exhibit increased proliferation and levels of ERK and cyclin D1 activation, which are blocked by a Rho inhibitor. In contrast, AKT activation was not altered. Moreover, Lbc expression confers increased resistance to genotoxic stress induced by doxorubicin, which is associated with upregulation of Bcl-2 and BAD phosphorylation, and this is reversed by a Rho inhibitor. In conclusion, these data support a role for Rho in liver cancer progression and resistance to therapy and may provide a basis for developing effective treatment for hepatocarcinoma. cell cycle; oncogenes

Published
2006

30. Rise and fall of HCV-related hepatocellular carcinoma in Italy: a long-term survey from the ITA.LI.CA centres

Author

Cazzagon, Nora, Trevisani, Franco, Maddalo, Gemma, Giacomin, Anna, Vanin, Veronica, Pozzan, Caterina, Del Poggio, Paolo, Rapaccini, Gianludovico, Di Nolfo, Anna M., Benvegnù, Luisa, Zoli, Marco, Borzio, Franco, Giannini, Edoardo G., Caturelli, Eugenio, Chiaramonte, Maria, Foschi, Francesco G., Cabibbo, Giuseppe, Felder, Martina, Ciccarese, Francesca, Missale, Gabriele, Baroni, Gianluca Svegliati, Morisco, Filomena, Pecorelli, Anna, and Farinati, Fabio

Published
2013
Full Text
View/download PDF

32. Characterization of ion transport mechanisms regulating intracellular pH in hepatic stellate cells

Author

Di Sario, Antonio, Baroni, Gianluca Svegliati, Bendia, Emanuele, D'Ambrosio, Letizia, Ridolfi, Francesco, Marileo, Julio Ricardo, Jezequel, Anne Marie, and Benedetti, Antonio

Subjects
Liver cells -- Physiological aspects, Ion pumps -- Research, Hydrogen-ion concentration -- Physiological aspects, Biological sciences
Abstract

Research demonstrates that intracellular pH regulation in rat hepatic stellate cells (HSC) is controlled by the sodium-hydrogen exchanger. Fluorescent pHi indicator 2',7'-bis(carboxyethyl)-5(6)-carboxyfluorescein labelling studies show that hepatic stellate cells are activated when a rise in pHi and sodium-hydrogen exchanger activity occurs. Platelet-derived growth factor stimulates the sodium-hydrogen exchanger. Subsequent HSC growth is slowed when amiloride is applied.

Published
1997

33. Plasma membrane order parameter in periportal and perivenular hepatocytes isolated from ethanol-treated rats

Author

Benedetti, Antonio, Tangorra, Annaluisa, Baroni, Gianluca Svegliati, Ferretti, Gianna, Marucci, Luca, Jezequel, Anne Marie, and Orlandi, Francesco

Subjects
Plasma membranes -- Physiological aspects, Liver cells -- Research, Biological sciences
Abstract

Investigations of membrane order parameter of plasma membrane in periportal (PP) and perivenular (PV) hepatocytes from rats on ethanol-containing or isocaloric carbohydrate diets revealed that PP and PV hapatocytes showed no variation in membrane order parameter in cell suspensions. In subconfluent monolayers, a lower plasma membrane order parameter was observed in PP hepatocytes. Cell membrane of the ethanol-treated rats showed greater resistance to the fluidizing-effect of ethanol.

Published
1994

34. Hepatectomy Versus Sorafenib in Advanced Nonmetastatic Hepatocellular Carcinoma

Author

Famularo, Simone, Donadon, Matteo, Cipriani, Federica, Giuliante, Felice, Ferri, Silvia, Celsa, Ciro, Ferrero, Alessandro, Foschi, Francesco Giuseppe, Baiocchi, Gian Luca, Biasini, Elisabetta, Campani, Claudia, Valle, Raffaele Dalla, Pellizzaro, Filippo, Baroni, Gianluca Svegliati, Raimondo, Giovanni, Mega, Andrea, Chiarelli, Marco, Maestri, Marcello, Gasbarrini, Antonio, Jovine, Elio, Grazi, Gian Luca, Rapaccini, Gian Ludovico, Ruzzenente, Andrea, Morisco, Filomena, Sacco, Rodolfo, Memeo, Riccardo, Crespi, Michele, Antonucci, Adelmo, Bernasconi, Davide P., Romano, Fabrizio, Griseri, Guido, Aldrighetti, Luca, Torzilli, Guido, and Trevisani, Franco

Published
2022
Full Text
View/download PDF

36. Correction to: Application of the Intermediate-Stage Subclassification to Patients With Untreated Hepatocellular Carcinoma (The American Journal of Gastroenterology, (2016), 111, 1, (70-77), 10.1038/ajg.2015.389)

Author

Giannini, Edoardo G., Moscatelli, Alessandro, Pellegatta, Gaia, Vitale, Alessandro, Farinati, Fabio, Ciccarese, Francesca, Piscaglia, Fabio, Rapaccini, Gian Lodovico, Di Marco, Maria, Caturelli, Eugenio, Zoli, Marco, Borzio, Franco, Cabibbo, Giuseppe, Felder, Martina, Sacco, Rodolfo, Morisco, Filomena, Missale, Gabriele, Foschi, Francesco Giuseppe, Gasbarrini, Antonio, Baroni, Gianluca Svegliati, Virdone, Roberto, Masotto, Alberto, and Trevisani, Franco

Subjects
Hepatology, Gastroenterology
Published
2018

37. Application of the Intermediate-Stage Subclassification to Patients With Untreated Hepatocellular Carcinoma

Author

Giannini, Edoardo G, Moscatelli, Alessandro, Pellegatta, Gaia, Vitale, Alessandro, Farinati, Fabio, Ciccarese, Francesca, Piscaglia, Fabio, Rapaccini, Gian Lodovico, Di Marco, Maria, Caturelli, Eugenio, Zoli, Marco, Borzio, Franco, Cabibbo, Giuseppe, Felder, Martina, Sacco, Rodolfo, Morisco, Filomena, Missale, Gabriele, Foschi, Francesco Giuseppe, Gasbarrini, Antonio, Baroni, Gianluca Svegliati, Virdone, Roberto, Masotto, Alberto, Trevisani, Franco, Bolondi, Luigi, Biselli, Maurizio, Caraceni, Paolo, Cucchetti, Alessandro, Domenicali, Marco, Gramenzi, Annagiulia, Magalotti, Donatella, Pecorelli, Anna, Serra, Carla, Venerandi, Laura, Gazzola, Alessia, Murer, Francesca, Pozzan, Caterina, Vanin, Veronica, Del Poggio, Paolo, Olmi, Stefano, Balsamo, Claudia, Vavassori, Elena, Benvegnu', Luisa, Capelli, Alberta, Golfieri, Rita, Mosconi, Cristina, Renzulli, Matteo, Bosco, Giulia, Roselli, Paola, Dell'Isola, Serena, Maria Ialungo, Anna, Rastrelli, Elena, Picciotto, Antonino, Savarino, Vincenzo, Mega, Andrea, Rinninella, Emanuele, Mismas, Valeria, Lanzi, Arianna, Cappa, Federica Mirici, Musetto, Alessandro, Neri, Elga, Stefanini, Giuseppe Francesco, Suzzi, Alessandra, Tamberi, Stefano, Triossi, Omero, Chiaramonte, Maria, Marchetti, Fabiana, Valerio, Matteo, Giannini, Edoardo G, Moscatelli, Alessandro, Pellegatta, Gaia, Vitale, Alessandro, Farinati, Fabio, Ciccarese, Francesca, Piscaglia, Fabio, Rapaccini, Gian Lodovico, Di Marco, Maria, Caturelli, Eugenio, Zoli, Marco, Borzio, Franco, Cabibbo, Giuseppe, Felder, Martina, Sacco, Rodolfo, Morisco, Filomena, Missale, Gabriele, Foschi, Francesco Giuseppe, Gasbarrini, Antonio, Baroni, Gianluca Svegliati, Virdone, Roberto, Masotto, Alberto, Trevisani, Franco, Bolondi, Luigi, Biselli, Maurizio, Caraceni, Paolo, Cucchetti, Alessandro, Domenicali, Marco, Gramenzi, Annagiulia, Magalotti, Donatella, Pecorelli, Anna, Serra, Carla, Venerandi, Laura, Gazzola, Alessia, Murer, Francesca, Pozzan, Caterina, Vanin, Veronica, Del Poggio, Paolo, Olmi, Stefano, Balsamo, Claudia, Vavassori, Elena, Benvegnù, Luisa, Capelli, Alberta, Golfieri, Rita, Mosconi, Cristina, Renzulli, Matteo, Bosco, Giulia, Roselli, Paola, Dell'Isola, Serena, Maria Ialungo, Anna, Rastrelli, Elena, Picciotto, Antonino, Savarino, Vincenzo, Mega, Andrea, Rinninella, Emanuele, Mismas, Valeria, Lanzi, Arianna, Cappa, Federica Mirici, Musetto, Alessandro, Neri, Elga, Stefanini, Giuseppe Francesco, Suzzi, Alessandra, Tamberi, Stefano, Triossi, Omero, Chiaramonte, Maria, Marchetti, Fabiana, and Valerio, Matteo

Subjects
Adult, Male, medicine.medical_specialty, Carcinoma, Hepatocellular, Prognosi, Aged, Aged, 80 and over, Female, Humans, Liver Neoplasms, Middle Aged, Neoplasm Staging, Prognosis, Prospective Studies, Young Adult, Gastroenterology, Intermediate stage, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, medicine, Carcinoma, 80 and over, Prospective cohort study, Hepatology, business.industry, Medicine (all), Settore MED/09 - MEDICINA INTERNA, Hepatocellular, medicine.disease, Prospective Studie, Liver Neoplasm, 030220 oncology & carcinogenesis, Hepatocellular carcinoma, 030211 gastroenterology & hepatology, Neoplasm staging, Liver cancer, business, Human
Abstract

OBJECTIVES:The Barcelona Clinic Liver Cancer (BCLC) intermediate stage (BCLC B) includes a heterogeneous population of patients with hepatocellular carcinoma (HCC). Recently, in order to facilitate treatment decisions, a panel of experts proposed to subclassify BCLC B patients. In this study, we aimed to assess the prognostic capability of the BCLC B stage reclassification in a large cohort of patients with untreated HCC managed by the Italian Liver Cancer Group.METHODS:We assessed the prognosis of 269 untreated HCC patients observed in the period 1987-2012 who were reclassified according to the proposed subclassification of the BCLC B stage from stage B1 to stage B4. We evaluated and compared the survival of the various substages.RESULTS:Median survival progressively decreased from stage B1 (n=65, 24.2%: 25 months) through stages B2 (n=105, 39.0%: 16 months) and B3 (n=22, 8.2%: 9 months), to stage B4 (n=77, 28.6%: 5 months; P

Published
2016

38. Patients with advanced hepatocellular carcinoma need a personalized management: A lesson from clinical practice

Author

Giannini, Edoardo G, Bucci, Laura, Garuti, Francesca, Brunacci, Matteo, Lenzi, Barbara, Valente, Matteo, Caturelli, Eugenio, Cabibbo, Giuseppe, Piscaglia, Fabio, Virdone, Roberto, Felder, Martina, Ciccarese, Francesca, Foschi, Francesco Giuseppe, Sacco, Rodolfo, Baroni, Gianluca Svegliati, Farinati, Fabio, Rapaccini, Gian Ludovico, Olivani, Andrea, Gasbarrini, Antonio, Di Marco, Maria, Morisco, Filomena, Zoli, Marco, Masotto, Alberto, Borzio, Franco, Benvegnù, Luisa, Marra, Fabio, Colecchia, Antonio, Nardone, Gerardo, Bernardi, Mauro, Trevisani, Franco, Rapaccini, Gian Ludovico (ORCID:0000-0002-6467-857X), Gasbarrini, Antonio (ORCID:0000-0002-7278-4823), Giannini, Edoardo G, Bucci, Laura, Garuti, Francesca, Brunacci, Matteo, Lenzi, Barbara, Valente, Matteo, Caturelli, Eugenio, Cabibbo, Giuseppe, Piscaglia, Fabio, Virdone, Roberto, Felder, Martina, Ciccarese, Francesca, Foschi, Francesco Giuseppe, Sacco, Rodolfo, Baroni, Gianluca Svegliati, Farinati, Fabio, Rapaccini, Gian Ludovico, Olivani, Andrea, Gasbarrini, Antonio, Di Marco, Maria, Morisco, Filomena, Zoli, Marco, Masotto, Alberto, Borzio, Franco, Benvegnù, Luisa, Marra, Fabio, Colecchia, Antonio, Nardone, Gerardo, Bernardi, Mauro, Trevisani, Franco, Rapaccini, Gian Ludovico (ORCID:0000-0002-6467-857X), and Gasbarrini, Antonio (ORCID:0000-0002-7278-4823)

Abstract

N/A

Published
2018

40. Nlrp3 Activation Induces Il-18 Synthesis and Affects the Epithelial Barrier Function in Reactive Cholangiocytes

Author

Maroni, Luca, primary, Agostinelli, Laura, additional, Saccomanno, Stefania, additional, Pinto, Claudio, additional, Giordano, Debora M., additional, Rychlicki, Chiara, additional, De Minicis, Samuele, additional, Trozzi, Luciano, additional, Banales, Jesus M., additional, Melum, Espen, additional, Karlsen, Tom H., additional, Benedetti, Antonio, additional, Baroni, Gianluca Svegliati, additional, and Marzioni, Marco, additional

Published
2017
Full Text
View/download PDF

41. Correlation between LDH levels and response to sorafenib in HCC patients: an analysis of the ITA.LI.CA database

Author

Sacco, Rodolfo, Mismas, Valeria, Granito, Alessandro, Musettini, Gianna, Masi, Gianluca, Caparello, Chiara, Vivaldi, Caterina, Felder, Martina, Bresci, Giampaolo, Fornaro, Lorenzo, Trevisani, Franco, Bernardi, Mauro, Bolondi, Luigi, Piscaglia, Fabio, Zoli, Marco, Biselli, Maurizio, Caraceni, Paolo, Cucchetti, Alessandro, Domenicali, Marco, Frigerio, Marta, Erroi, Virginia, Garuti, Francesca, Gramenzi, Annagiulia, Lenzi, Barbara, Magalotti, Donatella, Pecorelli, Anna, Venerandi, Laura, Farinati, Fabio, Giacomin, Anna, Vanin, Veronica, Pozzan, Caterina, Maddalo, Gemma, Ciccarese, Francesca, Del Poggio, Paolo, Olmi, Stefano, Di Marco, Mariella, Balsamo, Claudia, Di Nolfo, Maria Anna, Vavassori, Elena, Alberti, Alfredo, Benvegnã¹, Luisa, Gatta, Angelo, Gios, Maurizio, Golfieri, Rita, Giampalma, Emanuela, Mosconi, Cristina, Renzulli, Matteo, Rapaccini, Gian Lodovico, Bosco, Giulia, Caturelli, Eugenio, Roselli, Paola, Dell’isola, Serena, Ialungo, Anna Maria, Giannini, Edoardo G., Risso, Domenico, Marenco, Simona, Bruzzone, Linda, Savarino, Vincenzo, Picciotto, Antonino, Chiaramonte, Maria, Cabibbo, Giuseppe, Cammã , Calogero, Maida, Marcello, Di Martino, Arezia, Barcellona, Maria Rosa, Mega, Andrea, Gasbarrini, Antonio, Rinninella, Emanuele, Rotella, Virginia, Ginanni, Barbara, Foschi, Francesco Giuseppe, Lanzi, Arianna, Stefanini, Giuseppe Francesco, Dall’aglio, Anna Chiara, Cappa, Federica Mirici, Neri, Elga, Bassi, Paolo, Zanotti, Miriam, Missale, Gabriele, Biasini, Elisabetta, Porro, Emanuela, Morisco, Filomena, Guarino, Maria, Baroni, Gianluca Svegliati, Schiadã , Laura, Gemini, Stefano, Borzio, Francesco, Virdone, Roberto, Rodolfo Sacco, Valeria Misma, Alessandro Granito, Gianna Musettini, Gianluca Masi, Chiara Caparello, Caterina Vivaldi, Martina Felder, Giampaolo Bresci, Lorenzo Fornaro, for the Italian Liver Cancer (ITA.LI.CA) group: [.., Franco Trevisani, Mauro Bernardi, Luigi Bolondi, Fabio Piscaglia, Marco Zoli, Maurizio Biselli, Paolo Caraceni, Alessandro Cucchetti, Marco Domenicali, Marta Frigerio, Virginia Erroi, Francesca Garuti, Annagiulia Gramenzi, Barbara Lenzi, Donatella Magalotti, Anna Pecorelli, Laura Venerandi, Rita Golfieri, Emanuela Giampalma, Cristina Mosconi, Matteo Renzulli, and ]

Subjects
Oncology, Male, Pathology, Cancer Research, Clinical Biochemistry, Drug Resistance, L-Lactate dehydrogenase, Biomarkers, HCC, LDH, Sorafenib, Aged, Antineoplastic Agents, Biomarkers, Tumor, Carcinoma, Hepatocellular, Drug Resistance, Neoplasm, Female, Humans, Kaplan-Meier Estimate, L-Lactate Dehydrogenase, Liver Neoplasms, Middle Aged, Niacinamide, Phenylurea Compounds, ROC Curve, Retrospective Studies, Treatment Outcome, 2734, Antineoplastic Agent, Retrospective Studie, Neoplasm, Tumor, Liver Neoplasm, Hepatocellular carcinoma, Human, medicine.drug, Phenylurea Compound, medicine.medical_specialty, Sorafenib treatment, Pathology and Forensic Medicine, Text mining, Internal medicine, medicine, Carcinoma, neoplasms, business.industry, Retrospective cohort study, Hepatocellular, Biomarker, medicine.disease, digestive system diseases, business
Abstract

Background Lactate dehydrogenase (LDH) is a predictor of clinical outcome in hepatocellular carcinoma (HCC) patients. However, its predictive role in the clinical outcomes of sorafenib treatment has been poorly documented. The correlation between LDH levels and clinical outcomes in HCC patients treated with sorafenib and included in the nationwide Italian database ITA.LI.CA was investigated here. Patients and Methods The ITA.LI.CA database contains data for 5,136 HCC patients. All patients treated with sorafenib treatment and with available LDH values were considered. Overall survival (OS) and time to progression (TTP) were compared in patients with LDH levels above and below a defined threshold, determined through an ROC analysis. An explorative analysis investigated the relationship between the variation of LDH levels during treatment and response to sorafenib. Results Baseline LDH levels were available for 97 patients. The most accurate cutoff value for LDH concentration was 297 U/L. Patients with LDH values above (n=45) and below (n=52) this threshold showed equal OS (12.0 months) and TTP (4.0 months) values. Data on LDH levels during sorafenib treatment were reported for 10 patients. LDH values decreased in 3 patients (mean difference = -219 U/L) who also reported a prolonged OS and TTP versus those with unmodified/increased LDH (OS: NE (not evaluated) vs. 8.0 months, p=0.0083; TTP: 19.0 vs. 3.0 months, p=0.008). Conclusions The clinical benefits of sorafenib do not seem to be influenced by baseline LDH. According to the results of an explorative analysis, however, a decreased LDH concentration during sorafenib might be associated with improved clinical outcomes.

Published
2015

42. Cost-effectiveness of Pre-Transplant Sofosbuvir for Preventing Recurrent HCV Infection after Liver Transplantation

Author

Vitale, Alessandro, Spolverato, Gaya, Burra, Patrizia, De Feo Tullia Maria, Belli, Luca, Donato, Francesca, Baroni Gianluca Svegliati, Marianelli, Tania, Picciotto, Antonio, Toniutto, Pierluigi, Bhoori, Sherrie, Passigato, Nicola, Lucà Maria Grazia, Russo, FRANCESCO PAOLO, Cillo, Umberto, Angeli, P, for Liver Transplantation NITp working group, and Fagiuoli, Stefano

Subjects
Male, Waiting Lists, Cost-Benefit Analysis, Hepacivirus, Kaplan-Meier Estimate, sofosbuvir, Antiviral Agents, End Stage Liver Disease, Recurrence, Humans, cost-effectiveness analysis, hepatitis C virus infection, liver transplantation, recurrent HCV, Chronic Disease, Female, Hepatitis C, Chronic, Italy, Liver Failure, Liver Transplantation, Markov Chains, Middle Aged, Preoperative Period, Probability, Research Design, Retrospective Studies, Sofosbuvir, Treatment Outcome, Transplantation, Chronic, Hepatitis C
Published
2015

43. A 'systems medicine' approach to the study of non-alcoholic fatty liver disease

Author

Petta, Salvatore, Valenti, Luca, Bugianesi, Elisabetta, Targher, Giovanni, Bellentani, Stefano, Bonino, Ferruccio, Fargion, Silvia, Vanni, Ester, Ferrannini, Ele, Loguercio, Carmela, Lonardo, Amedeo, Marra, Fabio, Mancini, Marcello, Miele, Luca, Nobili, Valerio, Baroni, Gianluca Svegliati, Alessandro, Federico, Ballestri, Stefano, Brunetto, Maurizia Rossana, Coco, Barbara, Grieco, Antonio, Kondili, Loreta, Nascimbeni, Fabio, Prinster, Anna, Romagnoli, Dante, Taddei, Stefano, Vella, Stefano, Miele, Luca (ORCID:0000-0003-3464-0068), Grieco, Antonio (ORCID:0000-0002-0544-8993), Petta, Salvatore, Valenti, Luca, Bugianesi, Elisabetta, Targher, Giovanni, Bellentani, Stefano, Bonino, Ferruccio, Fargion, Silvia, Vanni, Ester, Ferrannini, Ele, Loguercio, Carmela, Lonardo, Amedeo, Marra, Fabio, Mancini, Marcello, Miele, Luca, Nobili, Valerio, Baroni, Gianluca Svegliati, Alessandro, Federico, Ballestri, Stefano, Brunetto, Maurizia Rossana, Coco, Barbara, Grieco, Antonio, Kondili, Loreta, Nascimbeni, Fabio, Prinster, Anna, Romagnoli, Dante, Taddei, Stefano, Vella, Stefano, Miele, Luca (ORCID:0000-0003-3464-0068), and Grieco, Antonio (ORCID:0000-0002-0544-8993)

Abstract

The prevalence of fatty liver (steatosis) in the general population is rapidly increasing worldwide. The progress of knowledge in the physiopathology of fatty liver is based on the systems biology approach to studying the complex interactions among different physiological systems. Similarly, translational and clinical research should address the complex interplay between these systems impacting on fatty liver. The clinical needs drive the applications of systems medicine to re-define clinical phenotypes, assessing the multiple nature of disease susceptibility and progression (e.g. the definition of risk, prognosis, diagnosis criteria, and new endpoints of clinical trials). Based on this premise and in light of recent findings, the complex mechanisms involved in the pathology of fatty liver and their impact on the short- and long-term clinical outcomes of cardiovascular, metabolic liver diseases associated with steatosis are presented in this review using a new "systems medicine" approach. A new data set is proposed for studying the impairments of different physiological systems that have an impact on fatty liver in different subsets of subjects and patients.

Published
2016

44. Curative therapies are superior to standard of care (transarterial chemoembolization) for intermediate stage hepatocellular carcinoma

Author

Pecorelli, Anna, Lenzi, Barbara, Gramenzi, Annagiulia, Garuti, Francesca, Farinati, Fabio, Giannini, Edoardo G., Ciccarese, Francesca, Piscaglia, Fabio, Rapaccini, Gian Lodovico, Di Marco, Maria, Caturelli, Eugenio, Zoli, Marco, Borzio, Franco, Sacco, Rodolfo, Cabibbo, Giuseppe, Felder, Martina, Morisco, Filomena, Gasbarrini, Antonio, Baroni, Gianluca Svegliati, Foschi, Francesco G., Biasini, Elisabetta, Masotto, Alberto, Virdone, Roberto, Bernardi, Mauro, Trevisani, Franco, Gasbarrini, Antonio (ORCID:0000-0002-7278-4823), Pecorelli, Anna, Lenzi, Barbara, Gramenzi, Annagiulia, Garuti, Francesca, Farinati, Fabio, Giannini, Edoardo G., Ciccarese, Francesca, Piscaglia, Fabio, Rapaccini, Gian Lodovico, Di Marco, Maria, Caturelli, Eugenio, Zoli, Marco, Borzio, Franco, Sacco, Rodolfo, Cabibbo, Giuseppe, Felder, Martina, Morisco, Filomena, Gasbarrini, Antonio, Baroni, Gianluca Svegliati, Foschi, Francesco G., Biasini, Elisabetta, Masotto, Alberto, Virdone, Roberto, Bernardi, Mauro, Trevisani, Franco, and Gasbarrini, Antonio (ORCID:0000-0002-7278-4823)

Abstract

Background & Aims: The Barcelona Clinic Liver Cancer intermediate stage (BCLC-B) of hepatocellular carcinoma (HCC) includes extremely heterogeneous patients in terms of tumour burden and liver function. Transarterial-chemoembolization (TACE) is the first-line treatment for these patients although it may be risky/useless for someone, while others could undergo curative treatments. This study assesses the treatment type performed in a large cohort of BCLC-B patients and its outcome. Methods: Retrospective analysis of 485 consecutive BCLC-B patients from the ITA.LI.CA database diagnosed with naïve HCC after 1999. Patients were stratified by treatment. Results: 29 patients (6%) were lost to follow-up before receiving treatment. Treatment distribution was: TACE (233, 51.1%), curative treatments (145 patients, 31.8%), sorafenib (18, 3.9%), other (39, 8.5%), best supportive care (BSC) (21, 4.6%). Median survival (95% CI) was 45 months (37.4-52.7) for curative treatments, 30 (24.7-35.3) for TACE, 14 (10.5-17.5) for sorafenib, 14 (5.2-22.7) for other treatments and 10 (6.0-14.2) for BSC (P<.0001). Independent prognosticators were gender and treatment. Curative treatments reduced mortality (HR 0.197, 95%CI: 0.098-0.395) more than TACE (HR 0.408, 95%CI: 0.211-0.789) (P<.0001) as compared with BSC. Propensity score matching confirmed the superiority of curative therapies over TACE. Conclusions: In everyday practice TACE represents the first-line therapy in an half of patients with naïve BCLC-B HCC since treatment choice is driven not only by liver function and nodule characteristics, but also by contraindications to procedures, comorbidities, age and patient opinion. The treatment type is an independent prognostic factor in BCLC-B patients and curative options offer the best outcome.

Published
2016

45. Years of life that could be saved from prevention of hepatocellular carcinoma

Author

Cucchetti, A, Trevisani, F., Bucci, L., Ravaioli, M., Farinati, F., Giannini, E. G., Ciccarese, F., Piscaglia, F., Rapaccini, Gian Ludovico, Di Marco, M., Caturelli, E., Zoli, M., Borzio, F., Sacco, R., Maida, M., Felder, M., Morisco, F., Gasbarrini, Antonio, Gemini, S., Foschi, F. G., Missale, G., Masotto, A., Affronti, A., Bernardi, M., Pinna, A. D., Bolondi, Luigi, Biselli, Maurizio, Caraceni, Paolo, Domenicali, Marco, Gramenzi, Annagiulia, Magalotti, Donatella, Pecorelli, Anna, Serra, Carla, Venerandi, Laura, Gazzola, Alessia, Murer, Francesca, Pozzan, Caterina, Vanin, Veronica, Del Poggio, Paolo, Olmi, Stefano, Balsamo, Claudia, Vavassori, Elena, Benvegnù, Luisa, Cappelli, Alberta, Golfieri, Rita, Mosconi, Cristina, Renzulli, Matteo, Bosco, Giulia, Roselli, Paola, Dell'Isola, Serena, Lalungo, Anna Maria, Rastrelli, Elena, Moscatelli, Alessandro, Pellegatta, Gaia, Picciotto, Antonino, Savarino, Vincenzo, Barcellona, Maria Rosa, Cammà, Calogero, Cabibbo, Giuseppe, Costantino, Andrea, Virdone, Roberto, Mega, Andrea, Rinninella, Emanuele, Mismas, Valeria, Dall'Aglio, Anna Chiara, Feletti, Valentina, Lanzi, Arianna, Cappa, Federica Mirici, Neri, Elga, Stefanini, Giuseppe Francesco, Tamberi, Stefano, Biasini, Elisabetta, Porro, Emanuela, Guarino, Maria, Baroni, Gianluca Svegliati, Schiadà, Laura, Chiaramonte, Maria, Marchetti, Fabiana, Valerio, Matteo, Rapaccini, Gian Ludovico (ORCID:0000-0002-6467-857X), Gasbarrini, Antonio (ORCID:0000-0002-7278-4823), Rinninella, Emanuele (ORCID:0000-0002-9165-2367), Cucchetti, A, Trevisani, F., Bucci, L., Ravaioli, M., Farinati, F., Giannini, E. G., Ciccarese, F., Piscaglia, F., Rapaccini, Gian Ludovico, Di Marco, M., Caturelli, E., Zoli, M., Borzio, F., Sacco, R., Maida, M., Felder, M., Morisco, F., Gasbarrini, Antonio, Gemini, S., Foschi, F. G., Missale, G., Masotto, A., Affronti, A., Bernardi, M., Pinna, A. D., Bolondi, Luigi, Biselli, Maurizio, Caraceni, Paolo, Domenicali, Marco, Gramenzi, Annagiulia, Magalotti, Donatella, Pecorelli, Anna, Serra, Carla, Venerandi, Laura, Gazzola, Alessia, Murer, Francesca, Pozzan, Caterina, Vanin, Veronica, Del Poggio, Paolo, Olmi, Stefano, Balsamo, Claudia, Vavassori, Elena, Benvegnù, Luisa, Cappelli, Alberta, Golfieri, Rita, Mosconi, Cristina, Renzulli, Matteo, Bosco, Giulia, Roselli, Paola, Dell'Isola, Serena, Lalungo, Anna Maria, Rastrelli, Elena, Moscatelli, Alessandro, Pellegatta, Gaia, Picciotto, Antonino, Savarino, Vincenzo, Barcellona, Maria Rosa, Cammà, Calogero, Cabibbo, Giuseppe, Costantino, Andrea, Virdone, Roberto, Mega, Andrea, Rinninella, Emanuele, Mismas, Valeria, Dall'Aglio, Anna Chiara, Feletti, Valentina, Lanzi, Arianna, Cappa, Federica Mirici, Neri, Elga, Stefanini, Giuseppe Francesco, Tamberi, Stefano, Biasini, Elisabetta, Porro, Emanuela, Guarino, Maria, Baroni, Gianluca Svegliati, Schiadà, Laura, Chiaramonte, Maria, Marchetti, Fabiana, Valerio, Matteo, Rapaccini, Gian Ludovico (ORCID:0000-0002-6467-857X), Gasbarrini, Antonio (ORCID:0000-0002-7278-4823), and Rinninella, Emanuele (ORCID:0000-0002-9165-2367)

Abstract

Background: Hepatocellular carcinoma (HCC) causes premature death and loss of life expectancy worldwide. Its primary and secondary prevention can result in a significant number of years of life saved. Aim: To assess how many years of life are lost after HCC diagnosis. Methods: Data from 5346 patients with first HCC diagnosis were used to estimate lifespan and number of years of life lost after tumour onset, using a semi-parametric extrapolation having as reference an age-, sex- and year-of-onset-matched population derived from national life tables. Results: Between 1986 and 2014, HCC lead to an average of 11.5 years-of-life lost for each patient. The youngest age-quartile group (18-61 years) had the highest number of years-of-life lost, representing approximately 41% of the overall benefit obtainable from prevention. Advancements in HCC management have progressively reduced the number of years-of-life lost from 12.6 years in 1986-1999, to 10.7 in 2000-2006 and 7.4 years in 2007-2014. Currently, an HCC diagnosis when a single tumour <2 cm results in 3.7 years-of-life lost while the diagnosis when a single tumour ≥2 cm or 2/3 nodules still within the Milan criteria, results in 5.0 years-of-life lost, representing the loss of only approximately 5.5% and 7.2%, respectively, of the entire lifespan from birth. Conclusions: Hepatocellular carcinoma occurrence results in the loss of a considerable number of years-of-life, especially for younger patients. In recent years, the increased possibility of effectively treating this tumour has improved life expectancy, thus reducing years-of-life lost.

Published
2016

47. A “systems medicine” approach to the study of non-alcoholic fatty liver disease

Author

Petta, Salvatore, primary, Valenti, Luca, additional, Bugianesi, Elisabetta, additional, Targher, Giovanni, additional, Bellentani, Stefano, additional, Bonino, Ferruccio, additional, Ferrannini, Ele, additional, Loguercio, Carmela, additional, Lonardo, Amedeo, additional, Marra, Fabio, additional, Mancini, Marcello, additional, Miele, Luca, additional, Nobili, Valerio, additional, Baroni, Gianluca Svegliati, additional, Alessandro, Federico, additional, Ballestri, Stefano, additional, Rossana Brunetto, Maurizia, additional, Coco, Barbara, additional, Grieco, Antonio, additional, Fargion, Silvia, additional, Kondili, Loreta, additional, Nascimbeni, Fabio, additional, Prinster, Anna, additional, Romagnoli, Dante, additional, Taddei, Stefano, additional, Vanni, Ester, additional, and Vella, Stefano, additional

Published
2016
Full Text
View/download PDF

48. Application of the Intermediate-Stage Subclassification to Patients With Untreated Hepatocellular Carcinoma

Author

Giannini, Edoardo G, primary, Moscatelli, Alessandro, additional, Pellegatta, Gaia, additional, Vitale, Alessandro, additional, Farinati, Fabio, additional, Ciccarese, Francesca, additional, Piscaglia, Fabio, additional, Rapaccini, Gian Lodovico, additional, Di Marco, Maria, additional, Caturelli, Eugenio, additional, Zoli, Marco, additional, Borzio, Franco, additional, Cabibbo, Giuseppe, additional, Felder, Martina, additional, Sacco, Rodolfo, additional, Morisco, Filomena, additional, Missale, Gabriele, additional, Foschi, Francesco Giuseppe, additional, Gasbarrini, Antonio, additional, Baroni, Gianluca Svegliati, additional, Virdone, Roberto, additional, Masotto, Alberto, additional, and Trevisani, Franco, additional

Published
2016
Full Text
View/download PDF

49. Individualized Treatment of Genotype 1 Naïve Patients: An Italian Multicenter Field Practice Experience

Author

Mangia, Alessandra, primary, Cenderello, Giovanni, additional, Orlandini, Alessandra, additional, Piazzolla, Valeria, additional, Picciotto, Antonio, additional, Zuin, Massimo, additional, Ciancio, Alessia, additional, Brancaccio, Giuseppina, additional, Forte, Paolo, additional, Carretta, Vito, additional, Zignego, Anna Linda, additional, Minerva, Nicola, additional, Brindicci, Gaetano, additional, Marignani, Massimo, additional, Baroni, Gianluca Svegliati, additional, Bertino, Gaetano, additional, Cuccorese, Giuseppe, additional, Mottola, Leonardo, additional, Ripoli, Maria, additional, and Pirisi, Mario, additional

Published
2014
Full Text
View/download PDF

50. Estimation of lead-time bias and its impact on the outcome of surveillance for the early diagnosis of hepatocellular carcinoma

Author

Cucchetti, Alessandro, primary, Trevisani, Franco, additional, Pecorelli, Anna, additional, Erroi, Virginia, additional, Farinati, Fabio, additional, Ciccarese, Francesca, additional, Rapaccini, Gian Lodovico, additional, Di Marco, Mariella, additional, Caturelli, Eugenio, additional, Giannini, Edoardo G., additional, Zoli, Marco, additional, Borzio, Franco, additional, Cabibbo, Giuseppe, additional, Felder, Martina, additional, Gasbarrini, Antonio, additional, Sacco, Rodolfo, additional, Foschi, Francesco Giuseppe, additional, Missale, Gabriele, additional, Morisco, Filomena, additional, Baroni, Gianluca Svegliati, additional, Virdone, Roberto, additional, Bernardi, Mauro, additional, and Pinna, Antonio D., additional

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results